Letter to Our Customers About the Pending Aesynt Acquisition
I want to let you know about some exciting news from Omnicell. Today we announced our intention to acquire Aesynt and to create an industry leader in flexible and scalable medication management solutions across the continuum of care. The acquisition supports our longstanding commitment to patient safety, efficiency, and provider growth, and we are excited to add Aesynt’s advanced solutions, including leading central pharmacy and IV compounding automation, to the Omnicell solutions portfolio. Combining our two companies will give us the tools and expertise to customize medication management solutions for any health care system pharmacy workflow.
I am equally excited to bring the very talented Aesynt team into the Omnicell organization. With their long-time leadership and expertise in medication management and robotics, I expect our powerful combination to accelerate innovation in our industry and benefit health care providers like you. Look for new solutions that help solve real challenges to be a significant result of this merger. Our press release provides additional details on the acquisition, which requires regulatory approval and is expected to close next year. We will update you as developments occur.
If you have any questions, please feel free to contact me.
Randall A. Lipps
Chairman, President, CEO and Founder
Omnicell CEO Randall Lipps and Aesynt CEO Kraig McEwen Discuss the Pending Acquisition:
Founded From the Heart
When his daughter was hospitalized at birth, Randall Lipps observed much inefficiency in the way hospital supplies were managed, and he saw that it prevented nursing staff from spending more time directly caring for patients. He founded Omnicell, Inc. in 1992 on the premise that better management of supplies and medications would improve a hospital’s standard of care by allowing clinicians to spend more time with their patients.
Mr. Lipps has served as Omnicell’s Chairman since the company’s founding, and in 2002 he assumed the additional position of President and Chief Executive Officer, taking a more active leadership role in the company’s operations.
Omnicell, Inc. Today
Omnicell is recognized as a leading provider of comprehensive, technologically advanced automation that enables health care facilities to acquire, manage, dispense, and deliver medications and supplies more effectively. Omnicell automation is used from the point of entry into the hospital through the central pharmacy, nursing units, operating room, procedural areas, and patient bedsides – as well as in long-term care sites.
For over 20 years the mission of Omnicell has focused on improving the medication and supply distribution process. More than 3,200 acute care customers worldwide have used Omnicell’s medication automation, supply chain, and analytics solutions to improve efficiency, reduce errors, and lower costs.
Omnicell non-acute care solutions, including the MTS brand, enable approximately 7,000 institutional and retail pharmacies worldwide to optimize productivity and control costs. Moreover, the innovative medication adherence packaging solutions can reduce costly hospital readmissions.
At Omnicell, delivering our technology is just the beginning. We are also committed to delivering the best customer experience. To ensure our customers gain the most utility from their Omnicell systems, we offer a suite of analytics software, a comprehensive training and education program, and first-rate customer support. Omnicell has been recognized with KLAS award every year since 2006.
Key product lines:
- Central pharmacy automation
- Medication management systems
- Supply management systems
- Business analytics
- Medication adherence packaging
For more information about Omnicell products and services, please explore our website, or contact us directly.